PCR-corrected parasitological cure at Day 28 (primary endpoint), Day 14 and Day 42 (secondary endpoints).

*In the PP analysis, patients with missing data were excluded and patients with new infections (determined by PCR) were considered successes at the first time point that this outcome was recorded, but were excluded thereafter.At Day 14, nine patients were non-evaluable in the CDA group: two earlier new infections (0.25%), three without PCR at Day 14, and four for ��other�� reasons. In the AL group, seven patients were non-evaluable: one earlier new infection (0.25%), five without PCR at Day 14, and one ��other��.At Day 28, 49 patients were non-evaluable in the CDA group: 26 earlier new infections (3.3%), ten without PCR at Day 28, and 13 ��other��. In the AL group, 21 patients were non-evaluable: ten earlier new infections (2.5%), seven without PCR at Day 28, and four ��other��.At Day 42, 135 patients were non-evaluable in the CDA group: 109 earlier new infections (13.7%), ten without PCR at Day 42, and 16 ��other��. In the AL group, 68 patients were non-evaluable: 56 earlier new infections (14.0%), five without PCR at Day 42, and seven ��other��.**In the ITT analysis, patients with missing data were treated as failures. Patients with new infections (determined by PCR) were considered successes at the first time point that this outcome was recorded and as failures thereafter.